Hey Subscriber,

Here is the quick review of the call yesterday

The most important issues for the company going forward are:

#1 They will complete a full#2 audit so the company becomes fully reporting in the next few weeks

#2 They estimate around $100 million of corporate profit from the completion of the wholesale PPE orders by Feb 15

#3 By FAR the best use of at least $50-$75 million of that cash is to buy back 1/3 or more of their 1.35 billion shares. The business is not capital intensive. Buying back shares will massively reduce the float and get the stock to $2 where they can uplist to Nasdaq listing. Reverse splitting the shares is not on the table--when you do that you make your stock a target for shorts--it hardly ever works.

With the CEO Paulson owning a majority of the shares, he is HIGHLY incentivized to use that cash to buy back shares and then cancel the certificates.

#4 Ex-Shark Tank DTC impresario Kevin Harrington will be mounting a large digital DTC campaign to sell their personal UVC wands starting in the new year.

#5 Most interesting item is the patent they filed and were granted for adding UV 222 light to a cellphone or tablet. Evidently, they beat Apple to the patent office by a few weeks. Adding far UV 222 light to a cell phone so you can zap and kill 99.99% of germs and pathogens anywhere land in a public space would obviously be a fantastic addition to any cell phone. They would of course license this tech as many of the cellphone manufacturers as possible, but if it was me knowing germaphobic China and Asia Pacific, they would be my first target along with the Big 3 Apple, Samsung, and Huawei.

The stock is bouncing around this morning, but 9-10 cents or better still work. They will report the total wholesale sales and gross profit in their 10K filing by Feb 15. That should be the next catalyst.

Happy New Year! End of year newsletter out by EOB today.

Toby